In one paragraphArticle in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
28 authors.
James YarmolinskyDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0003-4371-0873 Matthew A LeeNutrition and Metabolism Branch (NME), International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-6262-3447 Evelyn LauInstitute for Human Development and Potential, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-3281-8360 Ferran Moratalla-NavarroUnit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0001-7858-5713 Ruifang Li-GaoDepartment of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0003-0650-1351 Patrick C N RensenDivision of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-8455-4988 Ko Willems van DijkDivision of Endocrinology, Department of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.ORCID 0000-0002-2172-7394 Kostas K TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-8452-8472 Apiwat SangphukieoGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-5210-5398 Elmira EbrahimiGenomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.ORCID 0000-0003-0910-3447 Jochen HampeDepartment of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany.ORCID 0000-0002-2421-6127 Loïc Le MarchandEpidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, United States.ORCID 0000-0001-5013-980X Franzel J B van DuijnhovenDivision of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands.ORCID 0000-0001-8367-2352 Kala VisvanathanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.ORCID 0000-0002-0582-8005 Sabina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.ORCID 0000-0001-5201-172X Giovanna MasalaClinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.ORCID 0000-0002-5758-9069 Keren PapierCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.ORCID 0000-0002-4102-6835 Abbas DehghanDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0001-6403-016X Alexander G SmithDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0001-6418-613X Dennis WangInstitute for Human Development and Potential, Agency for Science, Technology and Research (A*STAR), Singapore, Republic of Singapore.ORCID 0000-0003-0068-1005 Victor MorenoUnit of Biomarkers and Susceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona, Spain.ORCID 0000-0002-2818-5487 Marc J GunterDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Ioanna TzoulakiDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.ORCID 0000-0002-4275-9328 Funding
Ceramides as novel drivers of metabolic dysfunction and colorectal cancerU01CA272529 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Mary Christine Playdon, SCOTT A SUMMERS · 2022 to 2026
$4.7MA*STAR (UIBR), the Academy of Medical Sciences Professorship APR7_1002Biomedical Research in Epidemiology and Public Health CIBERESPEngineering and Physical Sciences Research Council EP/V029045/1Instituto de Salud Carlos III ISCIIINational Institute for Health and Care Research Imperial Biomedical Research CentreNCI NIH HHS U01 CA272529Programa FORTALECE del Ministerio de Ciencia e Innovación FORT23/00032Spanish Association Against Cancer GCTRA18022MOREWorld Health Organization 001
6 · The paper itselfAbstract
backgroundThe role of lipid-perturbing medications in cancer risk is unclear.
methodsWe employed cis-Mendelian randomization and colocalization to evaluate the role of 5 lipid-perturbing drug targets (ANGPTL3, ANGPTL4, APOC3, CETP, and PCSK9) in risk of 5 cancers (breast, colorectal, head and neck, ovarian, and prostate). We triangulated findings using pre-diagnostic protein measures in prospective analyses in EPIC (977 colorectal cancer cases, 4080 sub-cohort members) and the UK Biobank (860 colorectal cancer cases, 50 177 controls). To gain mechanistic insight into the role of ANGPTL4 in carcinogenesis, we examined the impact of the ANGPTL4 p. E40K loss-of-function variant on differential gene expression in normal colon tissue in BarcUVa-Seq. Finally, we evaluated the association of colon tumor ANGPTL4 expression with cancer-specific mortality in TCGA.
resultsIn analysis of 78 473 cases and 107 143 controls, genetically proxied circulating ANGPTL4 inhibition was associated with reduced colorectal cancer risk (ORSD decrease = 0.76, 95% confidence interval [CI] = 0.66 to 0.89, P = 5.52 × 10-4, PPcolocalization = 0.83). This association was replicated using pre-diagnostic circulating ANGPTL4 concentrations in EPIC (hazard ratio [HR]log10 decrease = 0.91, 95% CI = 0.84 to 0.98, P = .01) and the UK Biobank (HRSD decrease = 0.93, 95% CI = 0.86 to 0.99, P = .03). In gene-set enrichment analysis of differential gene expression in 445 colon tissue samples, ANGPTL4 loss-of-function down-regulated several cancer-related biological pathways (PFDR < .05), including those involved in cellular proliferation, epithelial-to-mesenchymal transition, and bile acid metabolism. In analysis of 465 colon cancer patients, lower ANGPTL4 tumor expression was associated with reduced colorectal cancer-specific mortality risk (HRlog2 decrease = 0.66, 95% CI = 0.50 to 0.87, P = 2.92 × 10-3).
conclusionsOur integrative proteogenomic and observational analyses suggest a potential protective role of lower circulating ANGPTL4 concentrations in colorectal cancer risk. These findings support further evaluation of ANGPTL4 as a therapeutic target for colorectal cancer prevention.
Indexed as
Angiopoietin-Like Protein 4Colorectal NeoplasmsAgedBiomarkers, TumorCase-Control StudiesFemaleGene Expression Regulation, NeoplasticHumansMaleMendelian Randomization AnalysisMiddle AgedProspective StudiesAngiopoietin-Like Protein 4ANGPTL4 protein, humanBiomarkers, Tumor
Identifiers
PMID40511612
PMCPMC12415964
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390